Related Experiment Videos

Cardiovascular, Kidney, Liver, and Metabolic Interactions in Heart Failure: Breaking Down Silos

Chang Jie Mick Lee1,2, Leah B Kosyakovsky3, Muhammad Shahzeb Khan4,5

  • 1Cardiovascular Metabolic Disease Translational Research Programme, National University of Singapore, Yong Loo Lin School of Medicine, Centre for Translational Medicine, Singapore (C.J.M.L., R.S.-Y.F.).

Insights

Metabolic diseases significantly impact heart failure (HF) epidemiology, particularly HF with preserved ejection fraction. Understanding multiorgan interactions is crucial for managing complex HF cases and developing targeted therapies.

Area of Science:

  • Cardiology
  • Metabolic Diseases
  • Nephrology
  • Hepatology

Background:

  • Rising metabolic disease burden correlates with shifts in heart failure (HF) epidemiology, including increased HF with preserved ejection fraction.
  • Extracardiac factors and interorgan communication are critical in HF pathophysiology and heterogeneity.
  • Traditional approaches examining single comorbidities may miss shared mechanisms and bidirectional relationships in HF.

Purpose of the Study:

  • To review multiorgan interactions (cardiac, kidney, liver, metabolism) in HF development and progression.
  • To propose research strategies, including multiomics and machine learning, for understanding HF in the context of multiple organ disease.
  • To provide recommendations for clinical practice regarding screening and management of multiorgan involvement in HF.

Main Methods:

  • Literature review of multiorgan interactions in HF.
  • Analysis of preclinical HF models and their insights into multiorgan disease.
  • Review of current clinical trials and therapeutic agents targeting the cardiac-kidney-liver-metabolism axis.

Main Results:

  • Multiorgan interactions significantly complicate HF development and progression.
  • Advanced epidemiological approaches like multiomics and machine learning can better capture underlying mechanisms and interorgan crosstalk.
  • Existing preclinical models have advanced understanding of multiorgan disease in HF subtypes.

Conclusions:

  • A comprehensive understanding of cardiac, kidney, liver, and metabolic interactions is essential for managing HF.
  • Clinical practice requires integrated screening and management strategies for multiorgan involvement in HF.
  • Future clinical trials must be more inclusive, examining multimorbidity and incorporating multiorgan endpoints for greater clinical relevance.

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...